HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Kim, K.-Y. Articles by Leung, P. C K Search for Related Content PubMed PubMed Citation Articles by Kim, K.-Y. Articles by Leung, P. C K

Department of Obstetrics and Gynecology, British Columbia Children’s and Women’s Hospital, Child and Family Research Institute, University of British Columbia, 2H-30, 4490 Oak St Vancouver, Vancouver, British Columbia, Canada, V6H 3V5

(Requests for offprints should be addressed to P C K Leung; Email: peleung{at}interchange.ubc.ca)

In our previous studies, we demonstrated that ERK1/2 (extracellular signal-regulated protein kinase) and p38 MAPK (mitogen-activated protein kinase) are required for gonadotropin-releasing hormone (GnRH)-II-induced anti-proliferation of ovarian cancer cells. In the present study, we examined the role of the GnRH-I receptor, as well as the activation of protein kinase C (PKC), in the anti-proliferative effect induced by GnRH-I or II in ovarian cancer cells. Our results demonstrated that Antide, a GnRH-I antagonist, reversed the activation of ERK1/2 induced by GnRH-I or II and abolished the anti-proliferative effect of GnRH-I and II in ovarian cancer cells. Transfection of short-interfering RNA to abrogate the gene expression of the GnRH-I receptor reversed GnRH-I and II-induced anti-proliferation. These results indicate that GnRH-I or II induce anti-proliferation through the GnRH-I receptor in ovarian cancer cells. In addition, the activation of ERK1/2 by GnRH-I or II was mimicked by phorbol-12-myristate 13-acetate, a PKC activator. Pretreatment with GF109203X, an inhibitor of PKC, blocked GnRH-induced ERK1/2 activation and anti-proliferation. These results suggest that the activation of PKC is responsible for GnRH-induced ERK1/2 activation and anti-proliferation in ovarian cancer cells. Taken together, these results indicate that binding of GnRH-I and II to the GnRH-I receptor activates ERK1/2 through a PKC-dependent pathway and is essential for GnRH-induced anti-proliferation of ovarian cancer cells.

This article has been cited by other articles:

				S. L. Poon, G. T. Hammond, and P. C. K. Leung Epidermal Growth Factor-Induced GnRH-II Synthesis Contributes to Ovarian Cancer Cell Invasion Mol. Endocrinol., October 1, 2009; 23(10): 1646 - 1656. [Abstract] [Full Text] [PDF]

				S. Fister, A. R. Gunthert, B. Aicher, K. W. Paulini, G. Emons, and C. Grundker GnRH-II Antagonists Induce Apoptosis in Human Endometrial, Ovarian, and Breast Cancer Cells via Activation of Stress-Induced MAPKs p38 and JNK and Proapoptotic Protein Bax Cancer Res., August 15, 2009; 69(16): 6473 - 6481. [Abstract] [Full Text] [PDF]

				H.-M. Wu, J.-C. Cheng, H.-S. Wang, H.-Y. Huang, C. D. MacCalman, and P. C.K. Leung Gonadotropin-Releasing Hormone Type II Induces Apoptosis of Human Endometrial Cancer Cells by Activating GADD45{alpha} Cancer Res., May 15, 2009; 69(10): 4202 - 4208. [Abstract] [Full Text] [PDF]

				M. Montagnani Marelli, R. M. Moretti, S. Mai, J. Januszkiewicz-Caulier, M. Motta, and P. Limonta Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1761 - 1767. [Abstract] [Full Text] [PDF]

				H.-M. Wu, H.-S. Wang, H.-Y. Huang, Y.-K. Soong, C. D MacCalman, and P. C K Leung GnRH signaling in intrauterine tissues Reproduction, May 1, 2009; 137(5): 769 - 777. [Abstract] [Full Text] [PDF]

				C. D. White, M. Coetsee, K. Morgan, C. A. Flanagan, R. P. Millar, and Z.-L. Lu A Crucial Role for G{alpha}q/11, But Not G{alpha}i/o or G{alpha}s, in Gonadotropin-Releasing Hormone Receptor-Mediated Cell Growth Inhibition Mol. Endocrinol., November 1, 2008; 22(11): 2520 - 2530. [Abstract] [Full Text] [PDF]

				S. L. Poon, B.-S. An, W.-K. So, G. L. Hammond, and P. C. K. Leung Temporal Recruitment of Transcription Factors at the 3',5'-Cyclic Adenosine 5'-Monophosphate-Response Element of the Human GnRH-II Promoter Endocrinology, October 1, 2008; 149(10): 5162 - 5171. [Abstract] [Full Text] [PDF]

				K. Morgan, A. J. Stewart, N. Miller, P. Mullen, M. Muir, M. Dodds, F. Medda, D. Harrison, S. Langdon, and R. P. Millar Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to Agonist In vitro and In vivo Cancer Res., August 1, 2008; 68(15): 6331 - 6340. [Abstract] [Full Text] [PDF]

				S Darby, J Stockley, M M Khan, C N Robson, H Y Leung, and V J Gnanapragasam Expression of GnRH type II is regulated by the androgen receptor in prostate cancer Endocr. Relat. Cancer, September 1, 2007; 14(3): 613 - 624. [Abstract] [Full Text] [PDF]